PerkinElmer, Inc., today announced that it has acquired VisEn Medical, Inc., an in vivo molecular imaging technology company based in Bedford, Massachusetts.
The acquisition enables PerkinElmer to enhance its cellular imaging business, by expanding the Company’s technologies and capabilities downstream into preclinical research undertaken in academic institutes and pharmaceutical companies. VisEn’s proprietary fluorescence molecular imaging systems and reagents are currently used in applications involving research into cancer, inflammation, cardiovascular, skeletal and pulmonary diseases.
“We are very pleased to bring VisEn into the PerkinElmer organization,” said Richard Eglen, president, Bio-discovery, PerkinElmer. “VisEn provides a compelling offering in molecular imaging platforms and tools that are synergistic with PerkinElmer’s existing business. This acquisition broadens our product portfolio along the drug discovery pipeline, from basic disease-based research to preclinical drug discovery applications, through the addition of proprietary chemistries in the emerging and fast growing space of translational biomarker reagents.” He added, “This acquisition will advance further PerkinElmer’s mission to assist life sciences and pharmaceutical research in finding additional ways to develop new generations of safer and more effective drugs, as well as better diagnostic capabilities.”
